Bank of America
VERV

Bank of America’s Verve Therapeutics VERV Stock Holding History

Bank of America’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-129,600
Closed -$2.51M – 8296
2022
Q4 		$2.51M Buy
+129,600
New +$3.43M ﹤0.01% 4053

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America's VERV Position: Q3 2025 in Review

Bank of America sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 485,803 shares — an estimated $5.46M sold.

Bank of America first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $7.84M in Q4 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Bank of America reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of America sold 485,803 Verve Therapeutics shares in Q3 2025, an estimated $5.46M.
  • Bank of America first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Bank of America's Verve Therapeutics position peaked at $7.84M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.